Tadalafil study for pediatric PAH on efficacy, safety and pharmacodynamics
Not Applicable
- Conditions
- pediatric pulmonary arterial hypertension
- Registration Number
- JPRN-UMIN000005973
- Lead Sponsor
- ational Cerebral and Cardiovascular Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Those who are contraindicated for tadalafil
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method tadalafil activity(30min, 1hr, 2hr, 3hr, 4 or 5hr) after administration mean pulmonary arterial pressure and pulmonary arterial resistance of the same time points
- Secondary Outcome Measures
Name Time Method cyclic GMP level blood pressure, heart rate adverse effects (headache, flushing)